Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What sector does Immuneering Corporation Class A Common Stock (IMRX) operate in?
Immuneering Corporation Class A Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Immuneering Corporation Class A Common Stock (IMRX) current stock price?
As of the latest data, Immuneering Corporation Class A Common Stock stock price is $3.83, with a previous close of $3.71. Immuneering Corporation Class A Common Stock gained $0.12 in the last trading session, representing a 3.23% increase.
What is Immuneering Corporation Class A Common Stock (IMRX) current market capitalization?
Immuneering Corporation Class A Common Stock market cap is approximately 247.79 million.
What is Immuneering Corporation Class A Common Stock (IMRX) Earnings Per Share (EPS)?
The trailing EPS is -$0.93, and the forward EPS is -$1.26.
What is Immuneering Corporation Class A Common Stock (IMRX) EBITDA?
Immuneering Corporation Class A Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -17.19 million.
Does Immuneering Corporation Class A Common Stock (IMRX) pay dividends?
No. Immuneering Corporation Class A Common Stock does not pay a dividend.
What is Immuneering Corporation Class A Common Stock (IMRX) beta (volatility) score?
Immuneering Corporation Class A Common Stock has a beta of 0.392, indicating lower volatility than the overall market.
